Evidence map›Paper›PMID 21565740›Full record

Trial reportJACC. Cardiovascular imaging2011

Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.

Puja K Mehta, Pavel Goykhman, Louise E J Thomson, Chrisandra Shufelt, Janet Wei, Yuching Yang, Edward Gill, Margo Minissian, Leslee J Shaw, Piotr J Slomka and 3 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JACC. Cardiovascular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00570089 (Microvascular Coronary Disease In Women), which is not on this map. Cited by 80 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 6 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00570089 phase2completednot on this map

Microvascular Coronary Disease In Women: Impact Of Ranolazine

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2007 to 2009Enrolled20ConditionsMyocardial IschemiaArmsRanolazine, Placebo
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 syntheses or guidelines pooled it, 221 citations in OpenAlex.

  1. A systematic review of enrolment criteria and treatment efficacy for microvascular angina.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Ranolazine for stable angina pectoris.The Cochrane database of systematic reviews · 2017
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Guideline for Chronic Coronary Syndrome - 2025.Arquivos brasileiros de cardiologia · 2025
    Article
  15. Current Evidence-Based Treatment of Angina With Nonobstructive Coronary Arteries (ANOCA).Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Review
  16. Myocardial biomarkers in coronary microvascular dysfunction: Response to ranolazine.American heart journal plus : cardiology research and practice · 2025
    Article
  17. Review
  18. Review
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Puja K MehtaWomen's Heart Center, Cedars-Sinai Heart Institute, Los Angeles, California, USA.
Pavel Goykhman
Louise E J Thomson
Chrisandra Shufelt
Janet Wei
Yuching Yang
Edward Gill
Margo Minissian
Leslee J Shaw
Piotr J Slomka
Melissa Slivka
Daniel S Berman
C Noel Bairey Merz
Cedars-Sinai Smidt Heart Institute · USCedars-Sinai Medical Center · USEmory University · USImaging Center · US

Funding

ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI WANG, CHRISTINA C. · 1985 to 2011
$74.2M
Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular DysfunctionR01HL090957 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL, PEPINE, CARL J · 2008 to 2013
$3.5M
Functional MRI of the pharyngeal airwayR01HL068162 · NHLBI · UNIVERSITY OF ARIZONA · PI FREGOSI, RALPH FRANK · 2003 to 2005
$899k
ISCHEMIC HEART DISEASE IN WOMEN--CLINICAL CENTERN01HV068163 · HV · UNIVERSITY OF FLORIDA · PI PEPINE, CARL J · 1996 to 2001
$386k
ISCHEMIC HEART DISEASE IN WOMEN-CLINICAL CENTERN01HV068161 · HV · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROGERS, WILLIAM J · 1996 to 2000
$245k
EVAL OF ISCHEMIC HEART DISEASE IN WOMEN-CLINICAL CTRN01HV068164 · HV · ALLEGHENY-SINGER RESEARCH INSTITUTE · PI REICHEK, NATHANIEL · 1996 to 2001
–
EVAL OF ISCHEMIC HEART DISEASE IN WOMEN-CLINICAL CTR-N01HV68162-268068162N01HV068162 · HV · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1996 to 2005
–
NCRR NIH HHS M01 RR000425NCRR NIH HHS MO1-RR00425NHLBI NIH HHS N01 HV068161NHLBI NIH HHS N01 HV068162NHLBI NIH HHS N01 HV068163NHLBI NIH HHS N01 HV068164NHLBI NIH HHS N01-HV-68161NHLBI NIH HHS N01-HV-68162NHLBI NIH HHS N01-HV-68163NHLBI NIH HHS N01-HV-68164NHLBI NIH HHS R01 HL090957
6 · The paper itself

Abstract

objectivesWe conducted a pilot study for a large definitive clinical trial evaluating the impact of ranolazine in women with angina, evidence of myocardial ischemia, and no obstructive coronary artery disease (CAD).

backgroundWomen with angina, evidence of myocardial ischemia, but no obstructive CAD frequently have microvascular coronary dysfunction. The impact of ranolazine in this patient group is unknown.

methodsA pilot randomized, double-blind, placebo-controlled, crossover trial was conducted in 20 women with angina, no obstructive CAD, and ≥ 10% ischemic myocardium on adenosine stress cardiac magnetic resonance (CMR) imaging. Participants were assigned to ranolazine or placebo for 4 weeks separated by a 2-week washout. The Seattle Angina Questionnaire and CMR were evaluated after each treatment. Invasive coronary flow reserve (CFR) was available in patients who underwent clinically indicated coronary reactivity testing. CMR data analysis included the percentage of ischemic myocardium and quantitative myocardial perfusion reserve index (MPRI).

resultsThe mean age of subjects was 57 ± 11 years. Compared with placebo, patients on ranolazine had significantly higher (better) Seattle Angina Questionnaire scores, including physical functioning (p = 0.046), angina stability (p = 0.008), and quality of life (p = 0.021). There was a trend toward a higher (better) CMR mid-ventricular MPRI (2.4 [2.0 minimum, 2.8 maximum] vs. 2.1 [1.7 minimum, 2.5 maximum], p = 0.074) on ranolazine. Among women with coronary reactivity testing (n = 13), those with CFR ≤ 3.0 had a significantly improved MPRI on ranolazine versus placebo compared to women with CFR > 3.0 (Δ in MPRI 0.48 vs. -0.82, p = 0.04).

conclusionsIn women with angina, evidence of ischemia, and no obstructive CAD, this pilot randomized, controlled trial revealed that ranolazine improves angina. Myocardial ischemia may also improve, particularly among women with low CFR. These data document approach feasibility and provide outcome variability estimates for planning a definitive large clinical trial to evaluate the role of ranolazine in women with microvascular coronary dysfunction. (Microvascular Coronary Disease In Women: Impact Of Ranolazine; NCT00570089).

Indexed as

AcetanilidesAdenosineAgedCardiovascular AgentsCoronary CirculationCross-Over StudiesDouble-Blind MethodFeasibility StudiesFemaleHumansLos AngelesMagnetic Resonance ImagingMicrovascular AnginaMiddle AgedMyocardial IschemiaMyocardial Perfusion ImagingAcetanilidesAdenosineCardiovascular AgentsPiperazinesRanolazineVasodilator Agents

Identifiers

PMID21565740
PMCPMC6364688
OpenAlexW2042104057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.